- Previous Close
2.9400 - Open
2.9600 - Bid 3.0700 x 300
- Ask 3.1200 x 100
- Day's Range
2.9250 - 3.1000 - 52 Week Range
1.6300 - 8.8300 - Volume
906,292 - Avg. Volume
1,592,951 - Market Cap (intraday)
351.883M - Beta (5Y Monthly) 1.84
- PE Ratio (TTM)
-- - EPS (TTM)
-1.7000 - Earnings Date Nov 6, 2024 - Nov 11, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.58
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
www.fatetherapeutics.comRecent News: FATE
View More
Performance Overview: FATE
Trailing total returns as of 10/11/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: FATE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: FATE
View MoreValuation Measures
Market Cap
351.88M
Enterprise Value
147.57M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
26.08
Price/Book (mrq)
0.89
Enterprise Value/Revenue
11.98
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-20.50%
Return on Equity (ttm)
-42.10%
Revenue (ttm)
12.32M
Net Income Avi to Common (ttm)
-175.72M
Diluted EPS (ttm)
-1.7000
Balance Sheet and Cash Flow
Total Cash (mrq)
304.88M
Total Debt/Equity (mrq)
25.33%
Levered Free Cash Flow (ttm)
-66.67M
Research Analysis: FATE
View MoreCompany Insights: FATE
FATE does not have Company Insights
Research Reports: FATE
View MoreDaily – Vickers Top Buyers & Sellers for 01/17/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 01/14/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 01/13/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 01/13/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.